Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;73(1):13-17.
doi: 10.1016/j.jvs.2020.04.503. Epub 2020 May 17.

Cardiovascular disease due to novel coronavirus and the search for investigational therapies

Albeir Y Mousa  1 , Mike Broce  2 , B Daniel Lucas Jr  3
Affiliations

Cardiovascular disease due to novel coronavirus and the search for investigational therapies

Albeir Y Mousa et al. J Vasc Surg. 2021 Jan.

Abstract

Objective: The primary purpose of the study was to investigate and to summarize the registered trials that listed COVID-19 as the primary condition.

Methods: We performed a search on ClinicalTrials.gov using the independent search terms COVID-19, SARS, and SARS-CoV-2 and then downloaded the data file on March 23, 2020. All trials were downloaded to a csv file and searched for appropriateness.

Results: Of 124 registered trials, 56 (45.2%) were listed as recruiting. The majority (85 [68.5%]) were classified as interventional, 37 (29.8%) as observational, and one (0.8%) each as either expanded access: individual patients|treatment investigational new drug/protocol or expanded access: intermediate-size population|treatment investigational new drug/protocol. There were 67 (54.0%) trials that listed drug as the type of study. Immunologic and antiviral trials were the most common, representing approximately 30% and 21%, respectively. When immunologic and antiviral drugs were used alone or in combination, they represented 41.9% and 34.4%, respectively. Antimalarial agents are represented in 7.5% of trials. Approximately 14% of trials involved traditional Chinese medicine. The study agents used solely or in combination represented approximately 80% of therapeutic approaches to COVID-19.

Conclusions: There was a large and quick response on ClinicalTrials.gov to the COVID-19 outbreak. Many of the registered trials are currently recruiting new patients, whereas some will begin in the near future. Specific potential experimental therapies, including dosing and monitoring, might be found by reviewing content. Within ClinicalTrials.gov, patients, family members, health care professionals, and researchers can search and find ongoing and future trials for COVID-19.

Keywords: COVID-19; Clinical trials; Coronavirus; SARS-CoV-2; Therapy.

PubMed Disclaimer

Figures

Fig
Fig
Proposed start date for clinical trials.
See this image and copyright information in PMC

References

    1. Dhama K., Sharun K., Tiwari R., Dadar M., Malik Y.S., Singh K.P., et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother. 2020 Mar 18:1–7. [Epub ahead of print] - PMC - PubMed
    1. van der Werf S., Peltekian C. Emergence du coronavirus SARS-CoV-2: faire face a l'epidemie de COVID-19. Virologie (Montrouge) 2020;24:e12–e15. - PubMed
    1. Karan A. To control the covid-19 outbreak, young, healthy patients should avoid the emergency department. BMJ. 2020;368:m1040. - PubMed
    1. Su Y.J., Lai Y.C. Comparison of clinical characteristics of coronavirus disease (COVID-19) and severe acute respiratory syndrome (SARS) as experienced in Taiwan. Travel Med Infect Dis. 2020 Mar 14:101625. [Epub ahead of print] - PMC - PubMed
    1. Adhikari S.P., Meng S., Wu Y.J., Mao Y.P., Ye R.X., Wang Q.Z., et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9:29. - PMC - PubMed

MeSH terms